Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=program_officials" }, "data": [ { "type": "Grant", "id": "14850", "attributes": { "award_id": "2345178", "title": "Partnering to Recruit, Engage, Prepare, and Support New STEM Teachers for North Dallas Area Schools", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)", "Robert Noyce Scholarship Pgm" ], "program_reference_codes": [], "program_officials": [ { "id": 31530, "first_name": "Patrice", "last_name": "Waller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-01", "end_date": null, "award_amount": 1199934, "principal_investigator": { "id": 16099, "first_name": "Mary", "last_name": "Urquhart", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 199, "ror": "", "name": "University of Texas at Dallas", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 16094, "first_name": "John", "last_name": "Zweck", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 16097, "first_name": "Kate", "last_name": "York", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31531, "first_name": "Katherine", "last_name": "Donaldson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 199, "ror": "", "name": "University of Texas at Dallas", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This project aims to respond to the national need of preparing and retaining high-quality teachers. Teacher shortages in science, technology, engineering, and mathematics (STEM) are becoming increasingly dire in the aftermath of the Covid-19 pandemic and its impact on attitudes regarding teaching. New strategies are needed to rise to the challenges of recruiting, preparing, and retaining K–12 teachers. This program seeks to partner to recruit, engage, prepare, and support (PREPS) new teachers in the north Dallas area to increase the number of well-prepared science and mathematics teachers and retain them in the teaching profession. The PREPS project intends to investigate and disseminate effective strategies for recruitment of STEM majors into the teaching profession. PREPS also intends to investigate and disseminate effective strategies for support and retention of these newly prepared STEM teachers. <br/><br/>This project at the University of Texas at Dallas (UT Dallas) School of Natural Sciences and Mathematics includes partnerships with at least three high-need independent school districts (ISDs) in the north Dallas area of the Dallas-Fort Worth Metroplex (DFW): Garland ISD, Mesquite ISD, and Richardson ISD. The PREPS project is part of the UTeach Dallas STEM teacher certification preparation program. Project goals include strengthening collaborations with partner ISDs for 1) quality field experiences for preservice teachers, 2) effective induction support for new teachers, 3) investigation of new pathways for recruitment into and/or completion of teacher preparation, and 4) identification of barriers to new teacher retention and strategies to address these barriers. At the university, project goals include 1) targeted recruitment into teacher preparation of STEM majors in critical teacher shortages in mathematics and the sciences, 2) identification and dissemination of effective post-pandemic messaging for teacher recruitment from a pool of undergraduate STEM majors, 3) investigation of a potential partnership with the UT Dallas School of Science and Engineering for recruitment into the teaching profession of STEM majors in additional critical shortage areas such as computer science, and 4) systematic use of data for continuous improvement. UTeach Dallas PREPS also intends to explore direct recruitment of students in local, diverse, high-needs high schools into mathematics and science majors at UT Dallas and into UTeach Dallas. The project plans to disseminate findings to multiple university-based teacher preparation national and statewide networks. UTeach Dallas PREPS intends to provide up to 54 scholarships and 40 internships, with recipients anticipated to directly impact STEM learning for up to 27,000 students in their first five years of teaching in the Dallas-Fort Worth Metroplex. Participants are expected to positively impact K–12 students through internships and in their field experiences beginning as early as their first university semester. This Track 1: Scholarships and Stipends project is supported through the Robert Noyce Teacher Scholarship Program (Noyce). The Noyce program supports talented STEM undergraduate majors and professionals to become effective K-12 STEM teachers and experienced, exemplary K-12 teachers to become STEM master teachers in high-need school districts. It also supports research on the effectiveness and retention of K-12 STEM teachers in high-need school districts.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14851", "attributes": { "award_id": "2341932", "title": "HNDS-I: Developing a Large-Scale Data Platform for Processing Algorithms for Epidemic Modeling", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Social, Behavioral, and Economic Sciences (SBE)", "Human Networks & Data Sci Infr" ], "program_reference_codes": [], "program_officials": [ { "id": 31532, "first_name": "May", "last_name": "Yuan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-01", "end_date": null, "award_amount": 998028, "principal_investigator": { "id": 31534, "first_name": "Duncan", "last_name": "Watts", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 1043, "first_name": "VICTOR M", "last_name": "PRECIADO", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31533, "first_name": "Hamed", "last_name": "Hassani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project develops a data platform that collects data and tools for analysis that can be used to study, prevent and respond to pandemics. The name of this platform is the Data Access Platform for Human Mobility in Epidemiology (DAPHME). The DAPHME platform contains global positioning satellite (GPS) datasets that are privatized, so that data can be made available to researchers and policy-makers at minimal cost and without the need for extensive computing resources. Because more people will have access to the data and to repositories of tools for processing and analyzing the data, more people will be able to contribute to the understanding of the spread and prevention of disease. DAPHME promises to significantly improve the nation's capacity to model and mitigate the effects of future pandemics and is a strategic investment in public health infrastructure.<br/><br/>The DAPHME project improves access to mobility data through several coordinated actions. First, it creates and arranges data sharing agreements with various location data providers for platform users. Second, it reduces data access costs by providing analytical tools and servers, along with a subscription model that helps keep the platform financially self-sustaining. Third, it develops methods and mobility metrics specifically for epidemiological research to make analyses more efficient. Finally, it builds a community of researchers through networking to enhance their research projects and encourages the widespread development of new code and methods. The project will positively impact the replication of research results, the validation and broader use of data, and the effectiveness of tools designed to combat public health emergencies.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14856", "attributes": { "award_id": "1R37CA285794-01A1", "title": "Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31541, "first_name": "Avraham", "last_name": "Rasooly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 660742, "principal_investigator": { "id": 31542, "first_name": "Lauren Elizabeth", "last_name": "Colbert", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1420, "ror": "", "name": "UNIVERSITY OF TX MD ANDERSON CAN CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Cervical cancer remains the second most common cancer killer of women worldwide, with an annual incidence of more than 600,000 and an annual death rate of 300,000. Further, cervical cancer disproportionately affects communities of medically underserved and minority women within the US and abroad, and improved therapies are urgently needed. Primary and secondary prevention approaches are also variably effective – even prior to the COVID-19 pandemic, just 1 in 8 girls was vaccinated against human papillomavirus (HPV), the cause of 90% of cervical cancers. Vaccination rates also dropped sharply during the pandemic, even in the United States. Current World Health Organization (WHO) estimates of HPV vaccine uptake rates is 21%. The vast majority of cervical cancers that are diagnosed after primary and secondary prevention fail are locally advanced cervical cancer (LACC). Approximately 40% of women diagnosed with LACC will relapse and die of disease even with standard-of-care curative treatment, cisplatin-based chemoradiotherapy (CRT). CRT has remained the standard-of-care for more than two decades, and novel approaches have failed to improve outcomes. We have identified a critical prognostic factor, a bacteria called Lactobacillus iners (L. iners), in the cervical tumor microbiome, which rewires tumor metabolism to utilize lactate and is associated with treatment resistance and poor survival. Further, commensal Lactobacilli (lactic acid bacteria) in other tumor sites often driven by lactate, such as head and neck and lung cancers, also appear to lead to treatment resistance and poor survival. Our objective is to understand specifically how L. iners and other lactic acid bacteria influence cancer cell and immune cell metabolism using state-of-the-art proximity proteomics and mass cytometry (Aim 1). We will also test novel therapeutic approaches to target either tumor resident bacteria by eliminating or replacing specific bacterial species (Aim 2), or metabolic effects of tumor resident bacteria via local bacterial engineering or systemic metabolism targeting anti-cancer therapies (Aim 3). Targeting cervical tumor bacteria as a therapeutic (“Bugs as Drugs”) is a paradigm-shifting idea, capitalizing on the relative simplicity of the cervicovaginal microbiome and its tendency to be dominated by Lactobacillus species, and not only will this study lead to improved microbiome- based therapeutics to improve outcomes in cervical cancer, but this proof-of-concept model could be used to inform tumor microbiome-based therapeutics across cancer types.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14862", "attributes": { "award_id": "1R21AI180928-01A1", "title": "Serological and cellular immune response to SARS-CoV-2 vaccination in pediatric multiple sclerosis on immunotherapy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31547, "first_name": "MIREIA", "last_name": "Guerau", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2026-05-31", "award_amount": 181259, "principal_investigator": { "id": 31548, "first_name": "GRACE Yoonheekim", "last_name": "GOMBOLAY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 6490, "first_name": "Eliver", "last_name": "Ghosn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Mounting an effective antibody and cellular immune response to SARS-CoV-2 vaccination is critical for its efficacy to reduce the risk of severe complications and death in COVID-19. Patients with multiple sclerosis (pwMS) are at increased risk for severe COVID-19 and can have altered immune responses to SARS-CoV-2 vaccination. In addition, the type of disease-modifying therapy (DMT) further increases the risk for breakthrough COVID-19 infection and risk for severe COVID-19 and death in pwMS. For example, while anti- CD20 monoclonal antibodies (anti-CD20 mAbs) and sphingosine-1-phosphate receptor modulators (S1PMs) both decrease antibody response to SARS-CoV-2 in adult pwMS, the patient’s SARS-CoV-2-specific T-cell responses are blunted in S1PMs but not anti-CD20 mAbs. Although much is known about adult pwMS, limited data is available on vaccine responses in pediatric-onset multiple sclerosis (POMS) on similar therapies. Vulnerable and understudied, children have different immune systems than adults and can mount different immune responses to SARS-CoV-2 immunization. Here, we propose investigating how different immunotherapies (anti-CD20 mAbs vs. S1PM) affect vaccine response in pwMS across age. We will use our new multiparameter technology, flowBEAT, to measure the type (IgM, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE) and specificity (22 antigens, including structural and non-structural SARS-CoV-2 and HCoV proteins, and a panel to detect autoantibodies associated with COVID-19 severity) of antibody responses to SARS-CoV-2 vaccination and their ability to neutralize SARS-CoV-2 infection, along with pseudovirus neutralization assays (Aim 1). We will also characterize the phenotype and function of the patient’s SARS-CoV-2-specific B-cell and T-cell subsets using Hi-D flow and mass cytometry (Aim 2). Characterizing the SARS-CoV-2-specific humoral (antibodies) and cellular (memory B and T cell) responses after vaccination will determine whether the different immunotherapy regimens, anti-CD20 mAbs vs. S1PMs, can affect the development of a protective vaccine response, including robust neutralizing antibodies in pwMS across age. Our preliminary data suggest deficient IgG1 responses in POMS on S1PM but not on anti-CD20 mAbs. Thus, we hypothesize that the immunotherapy type (anti-CD20 mAbs vs. S1PM) will predict the quality of the memory B- and T-cell responses, including alterations in neutralizing antibodies, and that this protective immune response will depend on age. We expect this work to inform therapeutic decisions prescribed to vulnerable MS patients and guide future vaccine strategies to maximize vaccine efficacy in other patients on similar immunotherapies.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14863", "attributes": { "award_id": "1T32GM153182-01", "title": "University of Washington Medical Scientist Training Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31549, "first_name": "Andrea", "last_name": "Keane-Myers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 1798078, "principal_investigator": { "id": 31550, "first_name": "MARSHALL S.", "last_name": "HORWITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The University of Washington (UW) Medical Scientist Training Program (MSTP) was established in 1970 and is the only MD-PhD program in the five “WWAMI” states (Washington, Wyoming, Alaska, Montana, and Idaho) comprising a quarter of the landmass of the United States. Our program has thus far produced 285 graduates, 78% of whom have been employed in scientific research throughout their careers. Our goal is to leverage institutional and national resources to build an educational pipeline leading to the development and identification of a diverse group of talented trainees and equip them with the skills, mentorship, role models, and motivation required to advance the frontiers of biomedical science and technology. Among multiple accomplishments, students and graduates of our program created the Apple Macintosh computer and one of the first enzyme replacement therapies for metabolic disease, have provided fundamental insights into the nature of stem cells, the sequence and structure of the human genome, and the infectivity of SARS-CoV-2, and have led similarly successful MD-PhD programs elsewhere, thereby exponentially amplifying our program’s impact on training the next generation of physician-scientists. Our competitive program has grown to an annual class of 15, comprising approximately one-fifth of all medical students in Seattle. For each offer of admission, we receive over 23 training- grant-eligible applications. Of our 96 current trainees, 21% are from populations under-represented in medicine and 19% are from disadvantaged backgrounds. Our partnership with Morehouse School of Medicine enriches both institutions. Our trainees carry out their PhD research with UW faculty mentors at the UW, Fred Hutchinson Cancer Research Center (Hutch), Seattle Children's Hospital Research Institute, and Benaroya Research Institute. Current trainees' PhD departments and programs include Molecular and Cellular Biology, Neuroscience, Genome Sciences, Bioengineering, Computer Science, Molecular Engineering, Chemistry, and Epidemiology. They are mentored by a highly trained group of 81 well-funded, diverse, and gender-balanced distinguished faculty drawn from across ranks of junior to senior investigators, who emphasize and practice responsible, reproducible science in safe training environments. Our program integrates medical and graduate education, while reducing redundancy. Mean time to completion is 8.3 years and on a shortening trajectory, with minimal attrition of 2.6%. Over half of trainees receive NIH F30 independent fellowships. Over the last 15 years, graduates published a mean of 6.7 peer-reviewed papers, including 2.8 as first-authors, many of which are exceptionally impactful and have altered the course of research in their fields. Nearly all graduates go on to research-related residencies at leading institutions, predominantly in fields conducive to long-term retention in research. We continually evaluate our outcomes, measure our progress toward its overarching objective of producing resilient physician-scientists pushing the envelope at the interface of science and medicine, and iteratively evolve our program to stay at the forefront of evidence-based innovations in training practices.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14867", "attributes": { "award_id": "1OT2OD037640-01", "title": "All of Us Southern Network v.2.0", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 31553, "first_name": "Nicole", "last_name": "McNeil Ford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-02", "end_date": "2025-06-30", "award_amount": 3200000, "principal_investigator": { "id": 31554, "first_name": "MONA N.", "last_name": "FOUAD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31555, "first_name": "BRUCE R", "last_name": "KORF", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31556, "first_name": "Cora E", "last_name": "Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "2. Abstract The All of Us Southern Network (AoUSN) has been enrolling in the All of Us Research Program since 2018. It consists of sites in Alabama, Mississippi, and Louisiana, led by a team at the University of Alabama at Birmingham (UAB). The Network motivated by the idea that All of Us represents a unique opportunity to ensure that advances in precision medicine will benefit all people, and that there are large populations in our region who have been historically under\u0002represented in biomedical research. Our participating sites have extensive experience in earning trust and engaging individuals throughout the region, and we are well positioned to ensure that they are included in the All of Us Research Program. In addition to UAB, participating sites include UAB branch campuses in Huntsville, Selma, and Montgomery, AL; Cooper Green Mercy Health Services Authority in Birmingham; University of Alabama in Tuscaloosa; University of South Alabama in Mobile; University of Mississippi Medical Center in Jackson, MS; Louisiana State University Health Sciences Center (LSUHSC) and Tulane University in New Orleans, LA. Two of these sites, UAB, and LSUHSC, are also active in the Nutrition for Precision Health program. Dr. Stephen Sodeke from Tuskegee University serves as a Bioethics Consultant. The AoUSN has been a leader nationally in enrollment of individuals under\u0002represented in biomedical research, especially in terms of race, geography, and income. We were highly successful in enrollments pre-COVID-19, though it took some time for the Network to recover full capacity when enrollments resumed. The AoUSN is currently functioning in an extension phase from July 2023 - February 2024. During this time, it has consistently exceeded recruitment goals, reflecting in part the initiation of multiple innovations that will continue to expand through the funding period of the new OTA. These include: inpatient enrollment at UAB and several collaborating sites; establishment of a new site affiliated with UAB in Dothan, AL; opening “pop-up” enrollment sites throughout the region; use of several mobile clinical research units to reach participants in rural areas; use of Computer-Assisted Telephone Interviews (CATI) to facilitate retention; development of a relationship with Lakeshore Foundation in Birmingham, AL to engage and enroll persons with disabilities. We expect to continue and expand upon these innovations in the next five years. Inpatient enrollment has proved to be especially productive and efficient in terms of staff resources and will be expanded at UAB and at partner sites that have inpatient units. Our experience in setting up a new site in Dothan, AL prepares us to establish additional sites in larger cities in our region. We currently have four mobile units, including one exclusively dedicated to All of Us, and have another on order that will be dedicated to enrollment in rural areas of Alabama, Mississippi, and Louisiana. We have a new engagement lead (due to the untimely death of Dr. Shauntice Allen, our former Engagement Lead), Dr. Dina Avery, who has extensive connections with community leaders in our region and will work in an integrated manner with our outreach and enrollment teams to facilitate our ability to enroll participants in new areas. We have several active pilots intended to improve our ability to retain participants, including use of retention navigators and providing financial incentives for retention. Each of the AoUSN sites is prepared to enroll children (including four with affiliated dedicated children’s hospitals) and will support participant reassessments once these components are launched. In conclusion, the AoUSN remains committed to the principles of the All of Us Research Program, and especially its goal of partnering with diverse communities to ensure broad inclusion in the program. Precision medicine is a major theme in UAB and our affiliated institutions, and we see All of Us as a key opportunity to engage individuals from under-served communities to ensure that the benefits of precision medicine are widely available in our community.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14869", "attributes": { "award_id": "1R01EB035498-01A1", "title": "A universal intranasal nanoengineered therapy against airborne RNA viruses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 31558, "first_name": "JERMONT", "last_name": "Chen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-03", "end_date": "2028-04-30", "award_amount": 664392, "principal_investigator": { "id": 31559, "first_name": "Vinay Subhash", "last_name": "Mahajan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The past two decades have witnessed several air-borne viruses (SARS-CoV1, MERS, SARS- CoV2) that led to significant mortality. There is always a lag time before a vaccine is introduced. This lag creates an urgent need for a universal antiviral therapy that can be deployed rapidly as a prophylactic measure. Here, we propose to address this gap by engineering a novel intranasal- delivered nanoparticle that exerts an universal antiviral effect by activating a unique evolution- encoded innate immune state in nasal epithelial cells to provide early protection. There is a strong rationale for targeting nasal epithelium for an antiviral prophylaxis for air-borne viruses: (1) Nasal epithelium is the most common portal of entry of these pathogens; (2) The nasal cavity and nasopharynx contain some of the highest viral loads; and (3) Neutralizing the virus in the nasal epithelium has been shown to not only decrease viral load in both the nasal cavity and in distant sites, but potentially reduce transmission from asymptomatic individuals. While these studies validate nasal delivery as an ideal route of administration for viral prophylaxis, an effective universal antiviral therapy remains an unmet need. We hypothesize that activating an evolutionary conserved antiviral mechanism, i.e. the induction of IFN-Induced proteins with tetratricopeptide repeats 1 (IFIT1), can emerge as an effective universal prophylaxis against airborne viruses. This can be achieved by inhibiting CMTR2, a novel target, in the nasal epithelium. We will: (Aim 1) Engineer antiViral Response-Activating Nanoparticles (V-RANs) for intranasal delivery and test for inhibition of CMTR2 and induction of IFIT1; (Aim 2) Evaluate the antiviral efficacy and safety of V- RANs in mouse models of severe SARS coronavirus or pandemic flu infections; and in (Aim 3) Elucidate the molecular mechanism of V-RAN-induced antiviral response. Published reports and our preliminary results demonstrate the feasibility of this project. This study can lead to new insights into intranasal nanodelivery, and a novel antiviral prophylaxis that can shift the paradigm for early interventions in future pandemics.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14871", "attributes": { "award_id": "1F32HL168826-01A1", "title": "Low-energy cooling strategies to reduce the thermal, cardiovascular, and renal consequences of heat waves in the elderly.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31561, "first_name": "Wayne C.", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2027-06-30", "award_amount": 69080, "principal_investigator": { "id": 31562, "first_name": "Zachary John", "last_name": "McKenna", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1215, "ror": "", "name": "UT SOUTHWESTERN MEDICAL CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Heat waves cause a disproportionate number of deaths in the elderly relative to any other age group. Most of the hospitalizations and deaths in this population during heat waves are due to cardiovascular and renal complications linked to elevated thermal strain, and not directly due to hyperthermia per-se. Indoor cooling with an air conditioner remains the most effective strategy to prevent the deleterious health effects of heat waves. However, approximately 1 in 8 Americans do not have in-home air conditioners, and the rising household energy costs potentially makes air conditioning unaffordable for lower-income individuals. Also, power outages and industry/government-imposed rolling blackouts, along with COVID-19 related closures of public spaces, threaten region-wide access to air conditioning at times when it is most needed. Thus, there is a clear need to identify non-air conditioning dependent cooling modalities to attenuate excessive elevations in core body temperature and associated cardiovascular and renal stress in the elderly during heat wave conditions. The broad goal of this project is to test the efficacy of low-energy cooling strategies directed at mitigating the adverse thermal, cardiovascular, and potential renal consequences of heat wave exposure in the elderly. Aim 1 will test the hypothesis that skin wetting is an effective cooling modality to attenuate elevations in core body temperature and accompanying cardiovascular stress during heat waves in the elderly, while fan use may be detrimental depending on air temperatures and whether skin wetting is also employed. Aim 2 will determine if recognized impairments in thermoregulatory capacity and aging-related reductions in kidney function in the elderly will culminate in increased renal stress during heat wave exposures. The expected outcomes from this work will have a direct positive impact on the elderly by evaluating the efficacy of practical, low-energy cooling strategies that have the potential to save lives during heat waves. Further, we will provide critical information that comprehensively characterizes the extent of renal stress during simulated heat waves in elderly individuals. This research directly supports the mission of NIH in that we will uncover mechanistic physiological findings from human participants with the goal of translating these findings to guide individuals, caregivers, and communities on effective approaches to reduce heat related illness/injury. To ensure that this study was designed to maximize clinical relevance and my scientific training, I assembled a strong interdisciplinary clinical research/mentoring team consisting of expert integrative physiologists, physician-scientists, and a biostatistician. My primary goals during this fellowship are to complete the proposed project, master several technical skills (e.g., cardiac echocardiography, assessment of renal function/injury, etc.), improve my ability to obtain future extramural research funding, and publish research findings in peer-reviewed medical and physiology journals.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14873", "attributes": { "award_id": "1U18HS029937-01", "title": "Supporting Patients Recovering from COVID-19 (SPaRC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 31564, "first_name": "Latrice", "last_name": "Vinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 1000000, "principal_investigator": { "id": 31565, "first_name": "Ann Marie", "last_name": "Parker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: Long COVID impacts 10-30% of people after a SARS-CoV-2 infection, with potentially devastating long-term impact on quality of life. Moreover, Long COVID disproportionately affects minority, rural, older, and other at-risk populations. Multidisciplinary Long COVID clinics provide clinical care and offer infrastructure for evaluating promising interventions to improve Long COVID outcomes. The Johns Hopkins Post-Acute COVID-19 Team (JH PACT) is among the country's first and largest Long COVID programs. Via this AHRQ U18 proposal, JH PACT proposes the following Aims: (1) To deliver a comprehensive, multidisciplinary program (Supporting Patients Recovering from COVID, “SPaRC”) to patients with Long COVID, with an expanded focus on underserved populations. The SPaRC program will expand on the existing expertise of the JH PACT multidisciplinary Long COVID outpatient program to increase capacity and decrease wait times, with expanded services to underserved patient populations, including older adult, minority race/ethnicity, socioeconomically disadvantaged, and geographically distant and rural populations via enhanced partnerships with key existing organizations (e.g., Medicine for Greater Good, Center for Clinical Global Health Education). (2) To iteratively evaluate and refine the SPaRC Long COVID program to increase access and improve patient-centered, evidence-based care. The SPaRC program will be evaluated and iteratively refined in quarterly cycles via mixed methods evaluation (via patient data from electronic medical records and semi-structured qualitative interviews of patients/caregivers and staff/clinicians) to inform implementation strategies based on the “Expert Recommendations for Implementing Change” (ERIC) framework within a learning health system. In each review cycle, the implementation team and key SPaRC internal and external stakeholders will evaluate the program and outcomes and select goals for refinement and advancement for the next quarterly review cycle. An external Stakeholder Advisory Council, led by an independent Chair, will provide ongoing feedback via quarterly meetings throughout the project. (3) Partner with regional Long COVID stakeholders, including primary care providers (PCPs), to create and expand access to comprehensive, patient-centered, coordinated Long COVID care across the mid-Atlantic region. We will build a multi-disciplinary Long COVID provider-to-provider e-consult service, customized educational curriculum (delivered via both live and on-demand electronic formats), and continuing education toolkit for PCPs, in conjunction with key stakeholders (e.g., patients, caregivers, community leaders, and PCPs). JH PACT and the SPaRC Team include internationally-recognized experts in Long COVID care, patient outcomes assessment, implementation science, stakeholder/community engagement, and primary care education. JH PACT is ideally positioned to create a Long COVID Center of Excellence, leveraging the outstanding expertise available via Johns Hopkins Medicine, and to optimally engage with the AHRQ Learning Community.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15448", "attributes": { "award_id": "5U18HS029911-02", "title": "Advancing Long COVID Care in our Community through Access, Equity, and Collaboration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 31564, "first_name": "Latrice", "last_name": "Vinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": "2028-09-29", "award_amount": 931222, "principal_investigator": { "id": 28180, "first_name": "Abby Ling-Lee", "last_name": "Cheng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28181, "first_name": "Jonas", "last_name": "Marschall", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28182, "first_name": "Amy", "last_name": "McQueen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Long COVID manifests differently for each person and can contribute to disabling, life-changing symptoms such as extreme fatigue, cognitive dysfunction, breathing difficulty, and autonomic dysfunction in people across the age spectrum, including in people who were previously healthy and in people who had minimal or no symptoms associated with acute COVID-19 infection. Multidisciplinary Long COVID clinics were a mainstay of patient support during the initial phases of the COVID-19 pandemic, but as the pandemic is shifting to a new phase, care models must also evolve in order to meet the complex medical, rehabilitative, and social needs of the continually growing number of people who are affected by Long COVID. The purpose of this project is to transform an existing, university-based Long COVID clinic into a broader Long COVID community network in order to expand equitable access to care, improve the patient care experience, and support primary care practitioners. This project will invest in two particularly underserved populations: 1) the Black community in St. Louis, Missouri, which is a historically mistreated population who continues to be marginalized by previously sanctioned segregation practices; and 2) rural communities across Missouri. Aim 1 is to expand equitable access to Long COVID care by: 1) building clinical capacity, and 2) removing structural barriers to care. This will be accomplished by: 1) hiring additional clinicians for the Long COVID Clinic in order to reduce wait times; and 2) removing patient requirements for clinic evaluation that disproportionately affect underserved populations. Aim 2 is to improve the Long COVID care experience by: 1) streamlining care that crosses multiple disciplines and physical care sites, and 2) supporting patients’ social needs. This will be accomplished by: 1) supporting a clinical case manager to directly assist patients with coordinating medical care and connecting with community resources, and 2) iteratively assessing and addressing referral challenges between clinics. Aim 3 is to support primary care teams as they care for patients with Long COVID by co-creating: 1) educational resources for PCPs, and 2) streamlined communication and referral pathways between PCPs and specialty clinicians. This will be accomplished by engaging multiple key stakeholders to: 1) develop multi- modality educational materials related to Long COVID patient assessment and management; 2) disseminate materials via culturally and logistically preferred approaches (including via established, trusted community intermediaries and via an established ECHO (Enhanced for Community Healthcare Outcomes) virtual educational infrastructure); and 3) refine existing handoff processes to minimize the administrative workload on PCP teams and facilitate their ability to meet patients’ needs. Continuous stakeholder input, comprehensive data tracking, and iterative needs assessments using mixed methods approaches will facilitate ongoing project evaluation and adaptation in order to respond to the community’s evolving needs.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }